NotableEligibility criteria expanded, about 11 words
Trial sites expanded: 42 → 59 locations
MinorTrial sites expanded: 30 → 42 locationsv8
MinorTrial sites expanded: 12 → 30 locationsv7
MinorTrial sites expanded: 8 → 12 locationsv6
MinorStudy sites: 6 to 8v5
MinorTrial sites expanded: 3 → 6 locations
Start date changed from estimate of Apr 30, 2026 to Apr 27, 2026
v4
NotableRecruitment opened
Trial sites expanded: 0 → 3 locations
v3
Study First Submitted
Notable: the plan changed
Minor: routine updates
Endpoints
Primary
Annualized Bleed Rate (ABR) for Treated Bleeds Over the Main Study Treatment Period
Timeframe: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)
Secondary (22)
ABR for All Bleeds Over the Main Study Treatment Period
ABR for Treated Spontaneous Bleeds Over the Main Study Treatment Period
ABR for Treated Joint Bleeds Over the Main Study Treatment Period
Adjusted Mean Treatment Burden Domain Score in Comprehensive Assessment Tool of Challenges in Hemophilia (CATCH) Questionnaire - Adult Version at Month 8
ABR for Treated Target Joint Bleeds Over the Main Study Treatment Period
Show 17 moreShow less
Percentage of Participants with Zero Treated Bleeds Over the Main Study Treatment Period
Number of Injections and Dose per Bleed of Coagulation Factors or Bypassing Agent Administered to Treat a Bleed Over the Main Study Treatment Period
Annualized Injection Rate of FVIII or Bypassing Agent Over the Main Study Treatment Period
Annualized Consumption Rate of FVIII or Bypassing Agent Over the Main Study Treatment Period
Mean Treatment Burden Domain Score in CATCH Questionnaire - Adolescent Version at Month 8
Change From Baseline in Preoccupation Domain Score of the CATCH Questionnaire (Adult and Adolescent Versions)
Change From Baseline in Social Activity Impact Domain Score of the CATCH Questionnaire (Adult and Adolescent Versions)
Change From Baseline in Recreational Activity Impact Domain Score of the CATCH Questionnaire (Adult and Adolescent Versions)
Physical Impact Domain Score of the Treatment Administration Satisfaction Questionnaire (TASQ) at Specified Timepoints
Incidence and Severity of Adverse Events, With Severity Determined According To National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE V5.0) Grading Scale
Incidence and Severity of Thromboembolic Events and Thrombotic Microangiopathy
Incidence and Severity of Injection-Site Reactions
Incidence of Adverse Events Leading to Discontinuation of Assigned Study Treatment
Incidence of Severe Hypersensitivity, Anaphylaxis, or Anaphylactoid Reactions
Plasma Concentration of NXT007
Percentage of Participants With Anti-Drug Antibodies (ADAs) Against NXT007 at Baseline and During the Study
Percentage of Participants With Neutralizing ADAs Against NXT007
Arms and interventions
Main Study Treatment Period: NXT007 ProphylaxisExperimental
Participants randomized to this arm will receive NXT007 prophylaxis for the main study treatment period.
Main Study Treatment Period: Emicizumab ProphylaxisActive comparator
Participants randomized to this arm will receive emicizumab prophylaxis for the main study treatment period at 3 mg/kg once weekly (QW) for 4 weeks as loading doses, followed by maintenance dosing of either 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W). Loading doses are not required for participants who were taking emicizumab prior to study start.
After the main study treatment period, participants in the NXT007 arm will be able to continue with NXT007 dosing, and participants in the Emicizumab arm will be able to switch to NXT007, in the open-label extension period.
Combination products: NXT007
Drugs: Emicizumab
Sites
63 sites in 22 countries
United States 10, Spain 6, China 5, United Kingdom 5, France 4, Italy 4, Japan 4, Australia 3, Netherlands 3, Argentina 2, Belgium 2, Brazil 2, Germany 2, Ireland 2, New Zealand 2, Canada 1, Denmark 1, Hungary 1, Israel 1, South Africa 1, South Korea 1, Taiwan 1